04.05.2016 Evonik Industries AG  DE000EVNK013

DGAP-News: Evonik Industries AG: A solid first quarter - Outlook for 2016 confirmed


 
DGAP-News: Evonik Industries AG / Key word(s): Quarter Results Evonik Industries AG: A solid first quarter - Outlook for 2016 confirmed 04.05.2016 / 07:00 The issuer is solely responsible for the content of this announcement. --------------------------------------------------------------------------- Embargoed until: May 4, 2016, 7 a.m. May 4, 2016 Key Financial Data: January 1 to March 31, 2016 / Q1 2016 A solid first quarter-Outlook for 2016 confirmed - Adjusted net income EUR254 million - Adjusted EBITDA EUR565 million - Adjusted EBITDA margin at a very good level of 18.2 percent - Sales EUR3.1 billion Essen. Evonik did well in the first quarter in challenging business conditions. "Following an exceptionally strong performance in 2015, our earnings are now back in line with the good level of the preceding years. Our business is still doing well and our products are in demand in the market," said Klaus Engel, Chairman of the Executive Board of Evonik Industries. The Resource Efficiency segment posted a pleasing development: While sales were steady it was able to raise earnings. In the Nutrition & Care segment, lower volumes and declining world market prices resulted in a drop in both sales and earnings. Lower selling prices, mainly as a result of a reduction in raw material costs, also held back the development of the Performance Materials segment. Overall, the Evonik Group's sales contracted by 9 percent to EUR3,106 million (Q1 2015: EUR3,425 million). While demand for Evonik products was stable overall, selling prices declined by 7 percentage points. Adjusted EBITDA was EUR565 million, 13 percent lower than in the exceptionally strong prior-year period (Q1 2015: EUR650 million). The adjusted EBITDA margin remained very good at 18.2 percent, compared with 19.0 percent in the prior-year period. Adjusted EBIT fell 20 percent to EUR389 million. Adjusted net income was EUR254 million in the first quarter, down 21 percent from EUR320 million in the first quarter of 2015. Net income declined 6 percent to EUR240 million (Q1 2015: EUR256 million). Capital expenditures for property, plant and equipment were EUR160 million in the first quarter of 2016, 15 percent below the prior-year level of EUR189 million. In the first quarter of 2016, the free cash flow was EUR161 million, compared with EUR179 million in the prior-year period. Outlook confirmed Evonik's expectations for global economic conditions are unchanged: Overall the company anticipates slightly lower momentum in the global economy, with a year-on-year growth rate of 2.5 percent in 2016. In these conditions, Evonik is confirming its outlook for the full year: Following a very successful year in 2015, the company expects to report slightly lower sales in 2016 and adjusted EBITDA of between EUR2.0 billion and EUR2.2 billion. Segment performance In the first quarter of 2016, the Nutrition & Care segment's sales fell 15 percent to EUR1,047 million. Alongside lower volumes, the main reason for this was the decline in world market prices. Adjusted EBITDA was EUR293 million, which was below the very high prior-year level of EUR353 million. The adjusted EBITDA margin remains at an excellent level of 28.0 percent. Driven by good global demand, the Resource Efficiency segment registered pleasing volume growth, but selling prices declined slightly overall. Sales were virtually unchanged year-on-year at EUR1,120 million. Adjusted EBITDA improved 5 percent to EUR256 million. The adjusted EBITDA margin increased from 21.7 percent to a very good level of 22.9 percent. Sales declined 9 percent to EUR772 million in the Performance Materials segment. This was due to the continued decline in raw material prices, which led to a further reduction in selling prices. By contrast, volumes increased substantially. Adjusted EBITDA was 11 percent lower at EUR64 million. The adjusted EBITDA margin was 8.3 percent, down slightly from 8.5 percent in the first quarter of 2015. Evonik Group: Excerpt from the income statement (in EUR million) Q1 2016 Q1 2015 Change in % Sales 3,106 3,425 -9 Adjusted EBITDA 565 650 -13 Adjusted EBIT 389 485 -20 Adjustments -13 -37 Financial result -34 -63 Income before income taxes, continuing 342 385 -11 operations Income taxes -98 -115 Income after taxes, continuing operations 244 270 -10 Income after taxes, discontinued operations - -11 Income after taxes 244 259 -6 thereof attributable to non-controlling 4 3 interests Net income 240 256 -6 Adjusted net income 254 320 -21 Prior-year figures restated Segment performance Sales Adj. EBITDA Q1 2016 Q1 2015 Change Q1 2016 Q1 2015 Change in in in in in % EUR EUR in % EUR EUR million million million million Nutrition & Care 1,047 1,229 -15 293 353 -17 Resource 1,120 1,124 - 256 244 5 Efficiency Performance 772 851 -9 64 72 -11 Materials Services 166 207 -20 35 46 -24 Other operations 1 14 -83 -65 Group 3,106 3,425 -9 565 650 -13 Prior-year figures restated Employees by segment March 31, 2016 Dec. 31, 2015 Nutrition & Care 7,347 7,165 Resource Efficiency 8,652 8,662 Performance Materials 4,384 4,380 Services 12,710 12,668 Other operations 507 701 Group 33,600 33,576 Company information Evonik, the creative industrial group from Germany, is one of the world leaders in specialty chemicals. Profitable growth and a sustained increase in the value of the company form the heart of Evonik's corporate strategy. Its activities focus on the key megatrends health, nutrition, resource efficiency and globalization. Evonik benefits specifically from its innovative prowess and integrated technology platforms. Evonik is active in over 100 countries around the world. In fiscal 2015 more than 33,500 employees generated sales of around EUR13.5 billion and an operating profit (adjusted EBITDA) of about EUR2.47 billion. Disclaimer In so far as forecasts or expectations are expressed in this Investor Relations News or where our statements concern the future, these forecasts, expectations or statements may involve known or unknown risks and uncertainties. Actual results or developments may vary, depending on changes in the operating environment. Neither Evonik Industries AG nor its group companies assume an obligation to update the forecasts, expectations or statements contained in this release. Contact: Tim Lange Head of Investor Relations +49 201 177-3150 [email protected] Evonik Industries AG Rellinghauser Straße 1-11 45128 Essen Germany Phone +49 201 177-01 Telefax +49 201 177-3475 www.evonik.com Supervisory Board Dr. Werner Müller, Chairman Executive Board Dr. Klaus Engel, Chairman Dr. Ralph Sven Kaufmann Christian Kullmann Thomas Wessel Ute Wolf Registered office Essen Registered court Essen local court Commercial registry B 19474 VAT ID no. DE 811160003 --------------------------------------------------------------------------- 04.05.2016 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG. The issuer is solely responsible for the content of this announcement. The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Media archive at www.dgap-medientreff.de and www.dgap.de --------------------------------------------------------------------------- Language: English Company: Evonik Industries AG Rellinghauser Straße 1-11 45128 Essen Germany Phone: +49 (0) 201 177-01 Fax: +49 (0) 201 177-3475 E-mail: [email protected] Internet: www.evonik.com ISIN: DE000EVNK013, XS0911405784 WKN: EVNK01, A1TM7T Indices: MDAX Listed: Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Hamburg, Hanover, Munich, Stuttgart; Terminbörse EUREX; Luxemburg End of News DGAP News Service --------------------------------------------------------------------------- 460413 04.05.2016


Die wichtigsten Finanzdaten auf einen Blick
  2017 2018 2019 2020 2021 2022 2023e
Umsatzerlöse1 14.419,00 15.024,00 13.108,00 12.199,00 14.955,00 18.488,00 15.267,00
EBITDA1,2 2.357,00 2.150,00 2.153,00 1.837,00 2.246,00 2.510,00 1.598,00
EBITDA-Marge3 16,35 14,31 16,43 15,06 15,02 13,58
EBIT1,4 1.229,00 1.367,00 1.080,00 819,00 1.173,00 942,00 -243,00
EBIT-Marge5 8,52 9,10 8,24 6,71 7,84 5,10 -1,59
Jahresüberschuss1 734,00 954,00 2.127,00 479,00 767,00 555,00 -452,00
Netto-Marge6 5,09 6,35 16,23 3,93 5,13 3,00 -2,96
Cashflow1,7 1.551,00 1.704,00 1.321,00 1.727,00 1.815,00 1.650,00 1.594,00
Ergebnis je Aktie8 1,54 2,00 4,52 1,00 1,60 1,16 -1,00
Dividende8 1,15 1,15 1,15 1,15 1,17 1,17 1,15
Quelle: boersengefluester.de und Firmenangaben

  Geschäftsbericht 2023 - Kostenfrei herunterladen.  
1 in Mio. Euro; 2 EBITDA = Ergebnis vor Zinsen, Steuern und Abschreibungen; 3 EBITDA in Relation zum Umsatz; 4 EBIT = Ergebnis vor Zinsen und Steuern; 5 EBIT in Relation zum Umsatz; 6 Jahresüberschuss (-fehlbetrag) in Relation zum Umsatz; 7 Cashflow aus der gewöhnlichen Geschäftstätigkeit; 8 in Euro; Quelle: boersengefluester.de

Wirtschaftsprüfer: KPMG

INVESTOR-INFORMATIONEN
©boersengefluester.de
Evonik Industries
WKN Kurs in € Einschätzung Börsenwert in Mio. €
EVNK01 18,325 Halten 8.539,45
KGV 2025e KGV 10Y-Ø BGFL-Ratio Shiller-KGV
14,10 15,91 0,89 11,35
KBV KCV KUV EV/EBITDA
1,02 5,36 0,56 7,42
Dividende '22 in € Dividende '23e in € Div.-Rendite '23e
in %
Hauptversammlung
1,17 1,17 6,38 04.06.2024
Q1-Zahlen Q2-Zahlen Q3-Zahlen Bilanz-PK
08.05.2024 01.08.2024 06.11.2024 04.03.2024
Abstand 60Tage-Linie Abstand 200Tage-Linie Performance YtD Performance 52 Wochen
5,74% 4,29% -0,95% -3,86%
    
Weitere Ad-hoc und Unternehmensrelevante Mitteilungen zu Evonik Industries AG  ISIN: DE000EVNK013 können Sie bei EQS abrufen


Chemie , EVNK01 , EVK , XETR:EVK